After nabbing two AI-generated molecules, AstraZeneca returns to BenevolentAI with new collaboration

Roughly three years ago, AstraZeneca teamed up with London’s BenevolentAI to bring new drugs into its portfolio using the biotech’s AI and machine learning capabilities. Now that the original deal has borne fruit, the two companies are re-upping their collaboration.